- Global Pharma News & Resources

Journal Article Cites HemogloBind™ in Pig Development Study

MONMOUTH JUNCTION, NJ, July 9, 2019 -- Biotech Support Group reports on an article describing the simplicity and efficiency of their hemoglobin depletion technology for improving ELISA analysis from hemolyzed pig serum. The citation is:

Craig, J. R., et al. "A comparison of the anatomical and gastrointestinal functional development between gilt and sow progeny around birth and weaning." Journal of animal science (2019).

Gilt progeny (GP) often have restricted growth performance and health status in comparison to sow progeny (SP) from birth. To better understand underlying mechanisms, the study aimed to compare differences in growth and development between GP and SP in the first 24 h after birth and in the peri-weaning period. Because serum samples were quite hemolysed after collection and processing, it became necessary to use HemogloBind™ to allow for better detection of IgG by ELISA. The article states “As per the manufacturer’s instructions, 250 μL of Hemoglobind was added to 250 μL of hemolyzed serum, vortexed for 30 s before mixing via inversion for 10 min, and then centrifuged at 6,000 g for 2 min at 4°C. Purified serum was then aspirated and assessed in duplicate for IgG concentration … using a commercial ELISA kit (Bethyl Laboratories, Montgomery TX, USA).”  The authors conclude their findings suggest that the early development of GP may be delayed compared to SP, and that a number of the anatomical differences between GP and SP that exist after birth are also present at weaning.

“The large amount of hemoglobin can often interfere with ELISA measurements. This article demonstrates that HemogloBind™ can reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the underlying proteome, in this case IgG. As our technology does not rely on immuno-affinity, the product has the versatility to work on any species, as the authors demonstrate here on pigs” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemogloBind™, visit:

For information on all Hemoglobin Removal products: visit:

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to


Business Development Contact:

Matt Kuruc 732-274-2866,

Editor Details

Last Updated: 16-Jul-2019